TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

Stock Information for TFF Pharmaceuticals Inc - Ordinary Shares

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TFF Pharmaceuticals Inc - Ordinary Shares

TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration
TFF Pharmaceuticals Announces It Will Wind Down Operations
TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery
TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID
TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization
TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
TFF Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.